Artara Stock Today

TARA -  USA Stock  

USD 6.75  0.33  5.14%

Market Performance
0 of 100
Odds Of Distress
Less than 36
Artara Therapeutics is trading at 6.75 as of the 7th of December 2021, a 5.14% increase since the beginning of the trading day. The stock's open price was 6.42. Artara Therapeutics has about a 36 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Artara Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of December 2019 and ending today, the 7th of December 2021. Click here to learn more.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara Therapeutics, Inc. is headquartered in New York, New York. The company has 11.23 M outstanding shares of which 193.35 K shares are at this time shorted by private and institutional investors with about 2.99 trading days to cover. More on Artara Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Artara Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Artara Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Artara Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Artara Therapeutics generated a negative expected return over the last 90 days
Artara Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (43.02 M).
Artara Therapeutics currently holds about 84.67 M in cash with (31.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 67.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Purchase by Opaleye Management Inc of 1000 shares of Artara Therapeutics
Legal NameArtara Therapeutics
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Artara Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldFairly Valued
Artara Therapeutics (TARA) is traded on NASDAQ Exchange in USA and employs 27 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 70.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Artara Therapeutics's market, we take the total number of its shares issued and multiply it by Artara Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Artara Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 11.23 M outstanding shares of which 193.35 K shares are at this time shorted by private and institutional investors with about 2.99 trading days to cover. Artara Therapeutics currently holds about 84.67 M in cash with (31.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Artara Therapeutics Probability Of Bankruptcy
Ownership
Artara Therapeutics retains a total of 11.23 Million outstanding shares. Over half of Artara Therapeutics outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Artara Therapeutics. Please watch out for any change in the institutional holdings of Artara Therapeutics as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Artara Ownership Details

Artara Stock Price Odds Analysis

What are Artara Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Artara Therapeutics jumping above the current price in 90 days from now is about 81.45%. The Artara Therapeutics probability density function shows the probability of Artara Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Artara Therapeutics has a beta of 0.9103. This usually implies Artara Therapeutics market returns are sensitive to returns on the market. As the market goes up or down, Artara Therapeutics is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Artara Therapeutics is significantly underperforming DOW.
 Odds Down 6.75HorizonTargetOdds Up 6.75 
18.40%90 days
 6.75 
81.45%
Based on a normal probability distribution, the odds of Artara Therapeutics to move above the current price in 90 days from now is about 81.45 (This Artara Therapeutics probability density function shows the probability of Artara Stock to fall within a particular range of prices over 90 days) .

Artara Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Artara Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Artara Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Artara Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Opaleye Management IncCommon Shares2.6 M17.7 M
Ikarian Capital LlcCommon Shares480 K3.3 M
View Artara Therapeutics Diagnostics

Artara Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Artara Therapeutics market risk premium is the additional return an investor will receive from holding Artara Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Artara Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Artara Therapeutics' alpha and beta are two of the key measurements used to evaluate Artara Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Artara Stock Against Markets

Picking the right benchmark for Artara Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Artara Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Artara Therapeutics is critical whether you are bullish or bearish towards Artara Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Artara Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Artara Therapeutics information on this page should be used as a complementary analysis to other Artara Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Artara Stock analysis

When running Artara Therapeutics price analysis, check to measure Artara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artara Therapeutics is operating at the current time. Most of Artara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Artara Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Artara Therapeutics' price. Additionally, you may evaluate how the addition of Artara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Is Artara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artara Therapeutics. If investors know Artara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Artara Therapeutics is measured differently than its book value, which is the value of Artara that is recorded on the company's balance sheet. Investors also form their own opinion of Artara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Artara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artara Therapeutics' market value can be influenced by many factors that don't directly affect Artara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Artara Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.